Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
No holdings reported for quarter Q2 2019 |
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
INTRA-CELLULAR THERAPIES INC | 16 | Q3 2023 | 10.2% |
MICRON TECHNOLOGY INC | 16 | Q3 2023 | 6.7% |
ALPHABET INC | 16 | Q3 2023 | 5.8% |
ABBVIE INC | 16 | Q3 2023 | 7.9% |
REGENERON PHARMACEUTICALS | 16 | Q3 2023 | 5.5% |
ARGENX SE | 16 | Q3 2023 | 6.4% |
SPDR GOLD TRUST | 16 | Q3 2023 | 6.6% |
XENCOR INC | 16 | Q3 2023 | 4.1% |
BK OF AMERICA CORP | 16 | Q3 2023 | 5.4% |
ORACLE CORP | 16 | Q3 2023 | 3.2% |
View DCF Advisers, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-13 |
13F-HR | 2023-11-13 |
13F-HR | 2023-08-09 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-11 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-10 |
View DCF Advisers, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.